At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02617 TRANSTHERA-B
Not Yet Opened 09-03 16:08:21
10.090
+0.060
+0.60%
High10.240Low9.975Vol2.49M
Open10.160D1 Closing10.030Amplitude2.64%
Mkt Cap4.11BTradable Cap3.15BTotal Shares407.00M
T/O25.09MT/O Rate0.80%Tradable Shares312.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance
Bulletin Express  ·  09-02 19:23
TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance
TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist
Simply Wall St.  ·  08-27
TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist
TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million
Bulletin Express  ·  08-26
TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million
Transthera Sciences’ Tinengotinib Wins Conditional China NMPA Approval for Cholangiocarcinoma
Reuters  ·  08-26
Transthera Sciences’ Tinengotinib Wins Conditional China NMPA Approval for Cholangiocarcinoma
Transthera Sciences FY26 H1 Net Loss Narrows to RMB 95.47 Million; Revenue Rises to RMB 35.46 Million
Reuters  ·  08-26
Transthera Sciences FY26 H1 Net Loss Narrows to RMB 95.47 Million; Revenue Rises to RMB 35.46 Million
TRANSTHERA-B: Ching Fen Chan Tan Disposes of Shares, Long Position Falls to 5.76%
HK Disclosure  ·  08-25
TRANSTHERA-B: Ching Fen Chan Tan Disposes of Shares, Long Position Falls to 5.76%
TRANSTHERA-B: Ghalibo (PTC) Limited Disposes of Shares, Long Position Falls to 5.76%
HK Disclosure  ·  08-25
TRANSTHERA-B: Ghalibo (PTC) Limited Disposes of Shares, Long Position Falls to 5.76%
TRANSTHERA-B: Morningside Venture (I) Investments Limited Disposes of Shares, Long Position Falls to 5.76%
HK Disclosure  ·  08-24
TRANSTHERA-B: Morningside Venture (I) Investments Limited Disposes of Shares, Long Position Falls to 5.76%
TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 5.76%
HK Disclosure  ·  08-24
TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 5.76%
TransThera Sciences Schedules 26 August Board Meeting to Review 1H 2026 Results and Consider Interim Dividend
Bulletin Express  ·  08-14
TransThera Sciences Schedules 26 August Board Meeting to Review 1H 2026 Results and Consider Interim Dividend
TransThera Sciences Schedules Board Meeting to Review Interim Results
Reuters  ·  08-14
TransThera Sciences Schedules Board Meeting to Review Interim Results
TRANSTHERA-B: Future Industry Investment Fund II (Limited Partnership) Disposes of Shares, Long Position Falls to 5.85%
HK Disclosure  ·  08-10
TRANSTHERA-B: Future Industry Investment Fund II (Limited Partnership) Disposes of Shares, Long Position Falls to 5.85%
China NMPA Approves TransThera’s Yochanra for FGFR Inhibitor-Resistant Cholangiocarcinoma
Reuters  ·  08-07
China NMPA Approves TransThera’s Yochanra for FGFR Inhibitor-Resistant Cholangiocarcinoma
TRANSTHERA-B Shares Jump Over 12% in Morning Trading After Core Drug Tenagotinib Gets Market Approval
Deep News  ·  08-07
TRANSTHERA-B Shares Jump Over 12% in Morning Trading After Core Drug Tenagotinib Gets Market Approval
TransThera Wins China Marketing Approval for Bile Duct Cancer Drug
MT Newswires Live  ·  08-07
TransThera Wins China Marketing Approval for Bile Duct Cancer Drug
Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval
Market Focus  ·  08-07
Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval
Transthera-B secures NMPA approval for Je'ente in advanced bile duct cancer treatment
Stock News  ·  08-06
Transthera-B secures NMPA approval for Je'ente in advanced bile duct cancer treatment
Transthera Sciences (Nanjing) - Nmpa Grants Marketing Approval for Yochanra (Tinengotinib Tablets)
THOMSON REUTERS  ·  08-06
Transthera Sciences (Nanjing) - Nmpa Grants Marketing Approval for Yochanra (Tinengotinib Tablets)
Genecare Development Reduces Stake in TRANSTHERA-B, Sells 467,500 Shares at Approximately HK$12.58 Each
Stock News  ·  08-06
Genecare Development Reduces Stake in TRANSTHERA-B, Sells 467,500 Shares at Approximately HK$12.58 Each
TRANSTHERA-B: Morningside Venture (I) Investments Limited Sees Disposal of Shares, Long Position Falls to 6.87%
HK Disclosure  ·  08-06
TRANSTHERA-B: Morningside Venture (I) Investments Limited Sees Disposal of Shares, Long Position Falls to 6.87%

Introduction

Company Name.
TRANSTHERA-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
Issue price:
--